A Bet on Biomarin

There are few catalysts that move pharmaceuticals stocks as much as Food & Drug Administration approval of a much-anticipated drug. A thumbs-up from the government can send a company’s share price soaring. Of course, a thumbs-down can send it in the other direction too. Biomarin’sfate hangs in this same balance.

The Navato, Calif., company wants to bring to market a drug called Kuvan that was developed to treat pheylketonuria, which prevents the body from processing the essential amino acids in a lot of protein-containing foods. Cramer expects approval by the end of the year, “but I’m not 100% sure,” he said, “which is why this is still a speculative stock.”

There’s no treatment for PKU, as it’s called, other than a restrictive diet. So Kuvan would allow the 50,000 people in the developed world living with the condition to enjoy chicken, milk, eggs, cheese, even an ice cream sundae. Biomarin , which is working on the drug with Merck , would enjoy the benefits of Kuvan’s orphan-drug status, protecting the company from generic competition until 2015 in the U.S. and 2018 in Europe.

This isn’t the only drug Biomarin makes – it has treatments for MPS-I and MPS-IV as well – but if the FDA puts the kibosh on Kuvan, the stock “will get hurt badly,” Cramer said.

“Biomarin is the definition of a speculative trade,” he said. “I think you buy it for Kuvan, which should get approval and should be huge, although it still has a considerable amount of risk."

Questions for Cramer? madmoney@cnbc.com

Questions, comments, suggestions for the Mad Money website? madcap@cnbc.com

Contact Mad Money

  • Showtimes

    Monday - Friday 6p ET
    Saturday 8a, 1p, 7p SYD
    Sunday 12a, 1a, 8a, 7p SYD
    New Zealand
    Saturday 10a, 3p, 9p NZ
    Sunday 2a, 3a, 10a, 9p NZ
  • Jim Cramer is host of CNBC's "Mad Money" and co-anchor of the 9 a.m. ET hour of CNBC's "Squawk on the Street."

Mad Money Features

  • Grab the latest CNBC gear from the NBCUniversal Store!

  • Get a behind-the-scenes look at how Cramer formulates his investment advice. "Inside the Madness" is a column, which features e-mails and more with Cramer and his researcher Nicole Urken.

  • You’ve always wanted to hit the “Hallelujah!” button. Here’s your chance.

Mad Money Moments

Cramer's New Book